FXR activation aids fibrinolysis: targeting PAI-1 in obesity

In this issue of Blood, Li et al 1 report that tropifexor, an experimental farnesoid X receptor (FXR) agonist, has the potential to improve obesityassociated impairment of fibrinolysis through modulation of hepatic plasminogen activator inhibitor-1 (PAI-1) expression.

Authors

Alan J. Stewart (ORCID: https://orcid.org/0000-0003-4580-1840)

Institutions

University of St Andrews (GB)

Publication Details

Journal: Blood
Published: 2025-11-13
DOI: https://doi.org/10.1182/blood.2025030984
Primary Topic: Endoplasmic Reticulum Stress and Disease
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

FXR activation aids fibrinolysis: targeting PAI-1 in obesity

Alan J. Stewart

Nov 13, 2025

Blood

Endoplasmic Reticulum Stress and Disease

article

FXR activation aids fibrinolysis: targeting PAI-1 in obesity

Alan J. Stewart

November 13, 2025article en

Abstract

BloodVol. 146(20)

University of St Andrews (GB)

Openalex Percentile: Top 64%

Endoplasmic Reticulum Stress and Disease

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

FXR activation aids fibrinolysis: targeting PAI-1 in obesity — Alan J. Stewart · Blood (2025) | TGRS Research Map | TGRS